Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. - Wikidata - wikimedia - TriplyDB

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

http://www.wikidata.org/entity/Q34803284

about

Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260].Denosumab: mechanism of action and clinical outcomes Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams.Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.Loss of life years after a hip fracture.Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice.Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.Knowledge on Osteoporosis among Nurses Knowledge on osteoporosis of prescriber according to level of medical institute Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club Ocular side effects of bisphosphonates: A case report and literature review.Basic and clinical aspects of osteoporosis in inflammatory bowel disease.Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.Intravenous bisphosphonates for postmenopausal osteoporosis.Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study.Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.Review of ibandronate in the treatment of osteoporosis.The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men.Differences between the bisphosphonates for the prevention and treatment of osteoporosis.Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents Comparison of treatment effects between animal experiments and clinical trials: systematic review.Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials.Bone density testing: an under-utilised and under-researched health education tool for osteoporosis prevention?A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis Atypical femur fractures: a review of the evidence and its implication to clinical practice Osteoporosis medication profile preference: results from the PREFER-US study Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis.Assessing multiple medication use with probabilities of benefits and harms.

P2860

Q24198280-ACEF90DE-2DF5-4690-8E8C-65E1BE64192C Q24242258-7833C51B-1ABA-4872-A0B8-0FD8917D8050 Q24680238-6744E9A3-17F9-4982-A0C3-A8B61773D4DE Q24816597-7C31B92C-8372-46F7-B6F5-409C9AE26EBB Q25257203-520555DC-9E1F-4918-923D-08EB3D1BFA1B Q27015899-3F479F99-9001-4E03-A664-BD0D8890ECE1 Q33416959-82F842D9-F43A-4115-8FDB-7310F3106190 Q33481990-89752CC2-985C-4F4E-B7AC-B0985A86AB69 Q33482516-1B185591-DB72-484F-A916-6438504212C7 Q33660935-42815A0A-74B1-43E3-A0D8-7564451A8A5A Q33713146-2EEDBB95-3A31-4884-A537-5CCF59DEA9C5 Q33760576-8FAF0A90-3B57-4C2D-A91A-33BBCBAC67E3 Q33765409-886F3C1F-5AD6-451A-8627-B70BF19F3A9F Q33804834-AD5098DF-9E44-4FC0-B470-8C29B017C771 Q33822430-D071610B-875E-45AF-A4A6-D6394AD1E2AA Q33855542-B9F8A797-1ECB-4572-AFAD-35AB7671071B Q33966587-818EB8B5-5A7A-46B9-8CA6-9932A030E857 Q34099162-9A535C7F-540B-40DE-9F03-757E57F70A8E Q34194445-5F591883-038C-42E6-B68E-BDDCD93B4923 Q34225188-350C0D5E-56E1-490A-A828-B42E381FE88B Q34271979-379CB0D0-84E7-47BD-A980-FAB89FBE2F56 Q34373101-4D5DC7A8-8CF1-4503-9A15-6F37E8CF1014 Q34863964-121C8BDB-244B-4981-9E5C-E740DF534238 Q35033570-6AA0CE74-BD36-46C2-9678-7A4883BE5005 Q35050241-07938604-8E45-4C6D-8420-70461668BAD6 Q35076601-CA5CF71F-1423-4842-8B5F-FCD7255A8E9D Q35110262-87A9EC83-7912-4F69-B851-0176C697585B Q35166767-B957A1F4-B17B-4AF0-9D1F-53A2EE58E87D Q35229871-FF9EDE0D-34B3-4F67-9FD8-46FBA7AD9A34 Q35610097-231C6685-C2A8-4C05-AB41-E9DE46575F18 Q35643531-B36A10AB-F649-4684-8FB6-B3658B80F96C Q35671099-32A6BD0E-A871-44DB-A1EE-57485E5EF81C Q35779222-EF9AD387-5AC6-4CC0-B854-811FD621057E Q35954529-E769E671-85A6-4E78-BC81-583A759CE207 Q36045845-C89F87D0-4679-496B-B0F5-044B484DDC1F Q36059445-B72D71CB-E9A6-4EBE-B875-E9A0C066D584 Q36088579-CD81D4CD-A6FC-44E6-A22D-AF1D5E925009 Q36100929-C8BA84A5-8F50-4BDA-9D80-CEB9359D2242 Q36182874-BD7623F9-71C3-4A64-95A5-91392F0F5CAC Q36337373-E21CC343-5B76-4F2F-8766-5D787AB5A548

P2860

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

http://www.wikidata.org/entity/Q34803284

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Meta-analyses of therapies for ...... tment of postmenopausal women.

@ast

Meta-analyses of therapies for ...... tment of postmenopausal women.

@en

Meta-analyses of therapies for ...... tment of postmenopausal women.

@nl

type

label

Meta-analyses of therapies for ...... tment of postmenopausal women.

@ast

Meta-analyses of therapies for ...... tment of postmenopausal women.

@en

Meta-analyses of therapies for ...... tment of postmenopausal women.

@nl

prefLabel

Meta-analyses of therapies for ...... tment of postmenopausal women.

@ast

Meta-analyses of therapies for ...... tment of postmenopausal women.

@en

Meta-analyses of therapies for ...... tment of postmenopausal women.

@nl

P1433

Q34803284-3BC8B09D-4E5A-4242-96BA-21FDBF38170D

P1476

Q34803284-E259C1D5-A8F8-43AD-BA18-7E8D839C17D6

P2093

Q34803284-08A3D569-1518-4324-8FEF-BFF957A37BFD

Q34803284-1BE92FB6-2A83-478F-8FDD-5D652B404090

Q34803284-21D821CC-64BB-49E5-886E-E4C19F6F2FA1

Q34803284-2D3A40F1-2C52-4264-AFBE-889ACEF5FEA4

Q34803284-7996DE3F-4142-4431-BACE-FCFA3EC1D98D

Q34803284-A1A05E31-0257-489A-AC34-309422D8FBAD

Q34803284-C96EEC50-2F1E-4D70-A094-8CC2D608278D

Q34803284-DDCBEA9E-128C-4248-9372-0AB4E0C15385

Q34803284-E4E1DC13-9C85-430E-9616-D8061BAF14BE

Q34803284-F5E2B4D0-0DDB-4E87-B031-A11C7B44A890

P304

Q34803284-0EFC8012-94B9-476B-97BD-99AFC25EA8BE

P31

Q34803284-1b0f2b54-633c-484a-b523-2d7399659f2c

Q34803284-C1CE909F-EF5B-48E6-BD51-76F3E795C3AE

P356

Q34803284-29EDC730-D200-4729-B0BC-5CF5F927BD21

P433

Q34803284-433BD4FF-9BB3-4F0C-9A56-CC6CA301FE5B

P478

Q34803284-8F0A6BB7-5C4B-4135-9B3E-C608C53F05D9

P50

Q34803284-2013118B-5AE2-4615-B477-A0D9DC64B46D

Q34803284-6643BD4C-FD03-4C3E-BE45-A6CC2EEC334E

P577

Q34803284-E8B5D9F9-BF78-4E6C-8844-2E5E6E328C71

P5875

Q34803284-55EB8E0F-38FC-4542-B425-1668356816A8

P698

Q34803284-84FF241D-2640-4F6E-AA58-3AB200BB356D

P921

Q34803284-56FB81E4-7B64-46BA-9A99-042C5A3DAFF4

Q34803284-5FE96845-968C-49BE-8D94-1847E5748853

P356

P1433

Endocrine Reviews

P1476

Meta-analyses of therapies for ...... tment of postmenopausal women.

@en

P2093

Andrew Willan

http://www.w3.org/2001/XMLSchema#string

Ann Cranney

http://www.w3.org/2001/XMLSchema#string

Beverley Shea

http://www.w3.org/2001/XMLSchema#string

Dennis Black

http://www.w3.org/2001/XMLSchema#string

George Wells

http://www.w3.org/2001/XMLSchema#string

Jonathan Adachi

http://www.w3.org/2001/XMLSchema#string

Lauren Griffith

http://www.w3.org/2001/XMLSchema#string

Nicole Zytaruk

http://www.w3.org/2001/XMLSchema#string

Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group

http://www.w3.org/2001/XMLSchema#string

Vivian Robinson

http://www.w3.org/2001/XMLSchema#string

P304

508-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/ER.2001-2002

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

243972210

http://www.w3.org/2001/XMLSchema#string

P698

12202465

http://www.w3.org/2001/XMLSchema#string

P921